Effectiveness of inclisiran lipid-lowering therapy in patients with atherosclerotic cardiovascular disease in Moscow healthcare
Open Access
- 25 May 2024
- journal article
- research article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (6) , 5943
Abstract
Aim. To evaluate the effectiveness of PCSK9-targeted therapy (inclisiran, alirocumab, and evolocumab) in patients with atherosclerotic cardiovascular disease (ASCVD) and who did not achieve the target low-density lipoprotein cholesterol (LDL-C) level on basic therapy (statins in maximum tolerated doses and/or ezetimibe). Material and methods. This observational study included 50 patients receiving the inclisiran and 30 patients of the control group with ASCVD treated with PCSK9 inhibitors (alirocumab, n=1; evolocumab, n=29). In all participants, we assessed medical history data and initially performed electrocardiography, echocardiography, Doppler ultrasound of extracranial and lower limb arteries, and laboratory tests (complete blood count, biochemical and lipid profile). Three Moscow public health facilities took part in the study. Results. Data on achievement of primary and secondary endpoints by the 12 th month are presented. The study groups were comparable in basic clinical characteristics. In inclisiran group, a significant decrease in LDL-C level was found from 2,53±0,7 mmol/l initially to 1,29±0,5 mmol/l (by 49%), p=0,0002; the target LDL-C Conclusion. The final results are consistent with the intermediate data and indicate not only the possibility of early achievement of target LDL-C levels in PCSK9targeted combination therapy, but their maintenance with a favorable tolerability and safety profile.Keywords
This publication has 16 references indexed in Scilit:
- An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular DiseaseJACC, 2024
- Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level interventionAtherosclerosis, 2024
- Abstract 12945: Six-Month Adherence Among Early Inclisiran Initiators vs. Anti-PCSK9 mAbs Users: A Retrospective Analysis of US Claims DatabasesCirculation, 2023
- Disorders of lipid metabolism. Clinical Guidelines 2023Russian Journal of Cardiology, 2023
- Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI studyThe Lancet Regional Health - Europe, 2023
- Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 updateAtherosclerosis, 2022
- EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI studyEuropean Journal of Preventive Cardiology, 2020
- Inclisiran for the Treatment of Heterozygous Familial HypercholesterolemiaNew England Journal of Medicine, 2020
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL CholesterolNew England Journal of Medicine, 2020
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010